Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

KRSA

Bullish

Korsana Biosciences, Inc.

Healthcare·Biotechnology

$31.91

Current Price

$420M

Market Cap

—

P/E Ratio

$59.36

52W High

$7.19

52W Low

Company Profile

CEO

Peter Hecht

Employees

35

Year Founded

2024

Headquarters

Waltham, Massachusetts

Sector / Industry

Healthcare · Biotechnology

Key Statistics

Market Cap

$420M

Today's High

$32.12

Today's Low

$25.22

Open

$25.22

Previous Close

$24.92

52-Week High

$59.36

52-Week Low

$7.19

Today's Volume

113.8K

Avg. Volume

7.5K

Overnight Volume

8.2K

Shares Outstanding

13.2M

P/E Ratio

0.00

EPS

$-0.85

Beta

1.45

Dividend Yield

0.00%

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q2 20262026-08-13
Beat 12%
EPS Est.-0.25
EPS Actual-0.22
Rev. Est.$0.5M
Rev. Actual$0.6M
Q1 20262026-05-14
Missed -11%
EPS Est.-0.28
EPS Actual-0.31
Rev. Est.$0.5M
Rev. Actual$0.4M
Q4 20252026-03-26
Beat 3%
EPS Est.-0.30
EPS Actual-0.29
Rev. Est.$0.6M
Rev. Actual$0.7M
Q3 20252025-11-12
Missed -9%
EPS Est.-0.32
EPS Actual-0.35
Rev. Est.$0.4M
Rev. Actual$0.4M

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

Korsana Biosciences completed a reverse merger with Cyclerion Therapeutics alongside a $380 million private placement to develop its proprietary THETA blood-brain barrier-penetrant shuttle platform and lead asset KRSA-028 for Alzheimer's disease. Analysts from firms such as UBS have initiated coverage with a Buy rating and a $55.00 price target. While early clinical-stage biotechnology risk remains high due to ongoing cash burn and pipeline binary risks, substantial funding and novel central nervous system delivery mechanisms position the stock favorably.

7-Day Target

$36.50

+14.4%

30-Day Target

$45.00

+41.0%

6-Month Target

$55.00

+72.4%

AI Confidence

70%

Risk Level

High

Analyst Target

$85

Bull Case

Kura Sushi's aggressive unit expansion strategy and high brand loyalty position it to capture significant market share in the fast-casual dining sector, while its efficient, tech-driven labor model supports superior unit-level margins.

Bear Case

The company faces significant headwinds from rising labor costs, potential saturation in core markets, and the challenge of maintaining consistent food quality and service standards as it scales rapidly across diverse geographies.

Key Catalysts

  • Acceleration of new restaurant openings in high-traffic regions
  • Improvements in operating margins due to economies of scale
  • Successful implementation of menu innovations and seasonal promotions
  • Increased brand awareness driving higher comparable store sales

Key Risks

  • •Inflationary pressures on food and labor costs
  • •Dependency on proprietary technology systems
  • •Execution risks associated with rapid new store openings
  • •Competitive pressures from both traditional sushi restaurants and broader fast-casual chains

Company Overview

Kura Sushi USA, Inc. is a technology-enabled Japanese restaurant concept that serves authentic sushi through a unique revolving sushi bar platform. The company emphasizes a fun, interactive dining experience underpinned by proprietary robot-assisted technology to streamline kitchen operations.

Take this research further — free

Open KRSA in the full AI tools and run your own analysis: live charts, 7-day to 6-month targets, and risk checks. 15 minutes free, no card required.

Rather have it all, permanently?

30-day money-back guarantee • Secure payment by Square

KRSA Stock FAQ

What is the AI analysis for KRSA stock?

Stockinhood's AI generates multi-timeframe price targets for KRSA (Korsana Biosciences, Inc.), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is KRSA stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to KRSA based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Bullish. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for KRSA?

The AI-generated price target for KRSA is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $31.91. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in KRSA?

Inflationary pressures on food and labor costs Dependency on proprietary technology systems Execution risks associated with rapid new store openings Competitive pressures from both traditional sushi restaurants and broader fast-casual chains All risk analysis is informational only and not financial advice.

What sector is KRSA in?

Korsana Biosciences, Inc. (KRSA) operates in the Healthcare sector, specifically the Biotechnology industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.